Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509049 | 0.75 | — | — | |
| SCHEMBL3862393 | 0.75 | CA12 (0.38) | — | |
| SCHEMBL9543583 | 0.73 | CA12 (0.40) | — | |
| SCHEMBL27411129 | 0.73 | POLB (0.34) | — | |
| SCHEMBL28124493 | 0.71 | TDP1 (0.50) | ACHE | |
| SCHEMBL4413907 | 0.70 | — | — | |
| SCHEMBL6228460 | 0.70 | — | — | |
| SCHEMBL25450601 | 0.69 | — | — | |
| SCHEMBL3345449 | 0.69 | — | — | |
| SCHEMBL12744867 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1981889-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2014-01-15 | — | — | EP | disclosed |
| US-8163736-B2 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-2386559-A1 | Cytotoxiv agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254808-A1 | REFLECTIVE TOUCH DISPLAY PANEL AND MANUFACTURING METHOD THEREOF | AU OPTRONICS CORPORATION (TW) | 2011-10-20 | — | — | US | disclosed |
| EP-1813614-B1 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI SA (FR) | 2011-10-05 | — | — | EP | disclosed |
| EP-2371827-A1 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-10-05 | — | — | EP | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| EP-1981889-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085930-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | WO | disclosed |
| EP-1813614-A1 | Cytotoxic agents comprising new tomaymycin derivatives | Sanofi-Aventis (FR) | 2007-08-01 | — | — | EP | disclosed |
| EP-0734386-B1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | ABBOTT LAB (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-0734386-A1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | Abbott Laboratories (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5486525-A | ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995016687-A1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | ABBOTT LABORATORIES (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | TOMM70, TOMM34, TOMM40 | ACHE 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.